different. Spreading light.
the Indian pharmaceutical industry, recognised for its prowess in
generic pharmaceuticals, Troikaa is an outlier. Our company has
pursued the path of innovation in the domain of Novel Drug Delivery.
Relentless endeavours over the years have resulted in breakthrough
technologies, which have significantly improved the drug delivery
of several molecules.
Innovation has enabled Troikaa to grow at a rapid pace and will
continue to remain the key driver of our growth.
company's strength lies in its research and formulation development,
which has resulted in the development of proprietary technology
platforms like AquaTech (painless administration of drugs), Lipisol
(enables oily formulation to become water miscible), Matrix (sustained
release of small amounts of active ingredient over an extended period
of time from the tablet), etc. The formulations developed from these
platforms prove to be better than the conventional formulations
available in the market.
Every product formulation under these platforms is backed by multi-centric
clinical trials conducted at reputed institutions. Some of the products
developed from these innovative technologies include Aqua-E omega
(water soluble natural vitamin E), FENO-TG (Micro-solve technology),
Sitrus-LA (slow release of vitamin C), etc.
is through constant R&D that the company could develop Dynapar AQ
75mg/1ml, which is the world's first ever painless diclofenac injection.
The company enjoys patent of Dynapar AQ 1ml, the only 75mg/1ml Diclofenac
injection, in more than 70 countries including the USA. Troikaa's
said invention is well-appreciated world over and has gained immense
pride for the company in addition to the remarkable commercial success.
A non-aqueous formulation for topical delivery of Diclofenac has
been developed as a result of the company's perseverance to come
up with the best solution for the baffling issues of therapeutic
effectiveness and patient compliance. The company has applied for
patent protection for this breakthrough invention in around 95 countries
across the globe. Out of these, it has already been granted patent
in more than 50 countries including the European countries and Japan.
Commercially, Troikaa's said invention is turning out to be a game
changer in the field of pain management.